Ipilimumab plus temozolomide in metastatic melanoma.

Sapna Pradyuman Patel,Agop Y. Bedikian,Nicholas E. Papadopoulos,Wen-Jen Hwu,K. B. Kim,Jade Homsi,Michael A. Davies,Scott Eric Woodman,Laszlo Radvanyi,K. Woodard,Sandy Mahoney,Patrick Hwu

Ipilimumab plus temozolomide in metastatic melanoma.

2011

Sapna Pradyuman Patel
Agop Y. Bedikian
Nicholas E. Papadopoulos
Wen-Jen Hwu
K. B. Kim
Jade Homsi
Michael A. Davies
Scott Eric Woodman
Laszlo Radvanyi
K. Woodard
Sandy Mahoney
Patrick Hwu

8579 Background: Ipilimumab (Ipi), an antibody which releases T-cell suppression and enhances immune response, has shown an overall survival benefit in a Phase III trial of previously treated patie...

Keywords:

Temozolomide
Pathology
Ipilimumab
Melanoma
Cancer research
Medicine
Internal medicine
overall survival
Oncology
Immune system
previously treated
metastatic melanoma
Antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations